CAMBRIDGE, UK, March 11 /PRNewswire/ -- Purely Proteins Ltd (Cambridge, UK) today announced the initiation of its commercial protein purification program designed to accelerate and enhance the drug discovery and development process. The first products from this program are related to the Protein Tyrosine Phosphatase (PTP) protein family.
At the core of the program is Purely Proteins' TargetBASE database. This is a sophisticated, yet easy to use, informatics system that contains detailed information about all the known members of specific protein families. Crucially for the PTP program, TargetBASE comprehensively defines relationships between the PTPs, enabling pharmaceutical and biotechnology companies interested in this important therapeutic target group to better understand and exploit the links between different PTPs and the drugs that bind to them.
Complementing its in silico approach, Purely Proteins is using its extensive experience and proprietary internal capabilities in cloning, protein expression and protein purification to provide full length PTPs, PTP domains, and related synthetic peptides, for use in focused drug discovery R&D and drug screening programs. These are also available in kit form, bundled with a family of structurally defined PTP inhibitors for compound selectivity studies.
The PTPs are validated targets for drug discovery. PTP-1B (also known as PTPN1), for example, is a $billion drug target that is thought to modulate insulin signaling, deficiencies in which have been implicated in diabetes and obesity. Selective inhibitors of this phosphatase may become important drugs if potential toxicities associated with cross-reactivity with other members of this extended protein family can be avoided. The combination of Purely Proteins' informatics products, and their integration within a comprehensive platform of discovery tools, ranging from individual purified proteins to drug screening assays, will greatly facilitate the discovery and development of these important medicines.
Dr David Bailey, Chief Executive Officer of Purely Proteins, said: "I am very pleased to announce the expansion of Purely Proteins' existing drug discovery platforms to include the phosphatases. The new platform builds on our existing capabilities in the GPCR arena, and exemplifies Purely Proteins' commitment to providing a range of informatics-led, protein-based tools and products for use in drug discovery research. We are continuing to use our extensive knowledge and experience in developing essential tools for our clients in the pharmaceutical and biotechnology industries and will expand on these to include further informatics based products, families of recombinant proteins and other essential life science tools in the coming months."
Full details of Purely Proteins' product line can be obtained from the Purely Proteins website at http://www.purelyproteins.com/.
Purely Proteins has been established to exploit the increasing need for human proteins in pharmaceutical research. The company purifies suites of human proteins, both drug targets and bio-therapeutics, using proprietary processes that ensure both high purity and biological activity. Purely Proteins also offers drug-screening services, backed by state-of-the-art informatics, to examine therapeutic targeting to these proteins.
Dr David Bailey
Chief Executive Officer
254 Cambridge Science Park
Tel: +44 1223 426400
Fax: +44 1223 426003
Purely Proteins Ltd